BridgeBio Pharma (NASDAQ:BBIO) Stock Sale Reported by Rep. Gilbert Ray Cisneros, Jr.

Key Points

• Rep. Gilbert Cisneros Jr. sold $1,001–$15,000 of BridgeBio Pharma shares on September 29 through a Bank of America trust account, alongside several other stock purchases and sales.
• BridgeBio shares opened at $63.30, with a 52-week range of $52.75 to $93.42. The company’s latest quarter showed revenue rising 120.4% year over year to $243.68 million, but its $0.78 loss per share missed analyst expectations.
• Analysts maintain a “Moderate Buy” consensus, with 21 Buy, two Hold, and one Sell rating and an average price target of $105.42; institutional investors own 99.85% of the stock.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). In a filing disclosed on October 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in BridgeBio Pharma stock on September 29th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of Benchmark Electronics NYSE: BHE on 10/1/2026.
• Sold $1,001 - $15,000 in shares of Oxford Industries NYSE: OXM on 9/29/2026.
• Sold $1,001 - $15,000 in shares of Semtech NASDAQ: SMTC on 9/29/2026.
• Sold $15,001 - $50,000 in shares of ITT NYSE: ITT on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Tandem Diabetes Care NASDAQ: TNDM on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Cytokinetics NASDAQ: CYTK on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Ultragenyx Pharmaceutical NASDAQ: RARE on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of YETI NYSE: YETI on 9/29/2026.
• Sold $1,001 - $15,000 in shares of AtriCure NASDAQ: ATRC on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Alkermes NASDAQ: ALKS on 9/29/2026.

BridgeBio Pharma Stock Performance

Shares of BridgeBio Pharma stock opened at $63.30 on Wednesday. BridgeBio Pharma, Inc. has a 1 year low of $52.75 and a 1 year high of $93.42. The business has a 50 day moving average price of $73.77 and a 200 day moving average price of $73.44.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.20). The business had revenue of $243.68 million during the quarter, compared to the consensus estimate of $220.91 million. During the same period last year, the firm earned ($0.95) earnings per share. The business's quarterly revenue was up 120.4% compared to the same quarter last year. On average, analysts anticipate that BridgeBio Pharma, Inc. will post -2.66 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in BBIO. First Bank & Trust raised its holdings in shares of BridgeBio Pharma by 1.6% during the second quarter. First Bank & Trust now owns 8,797 shares of the company's stock valued at $655,000 after buying an additional 142 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of BridgeBio Pharma by 13.8% in the second quarter. GAMMA Investing LLC now owns 1,646 shares of the company's stock valued at $123,000 after buying an additional 199 shares during the period. IFP Advisors Inc lifted its holdings in BridgeBio Pharma by 44.8% in the 2nd quarter. IFP Advisors Inc now owns 1,160 shares of the company's stock valued at $86,000 after acquiring an additional 359 shares during the last quarter. Silvant Capital Management LLC bought a new stake in shares of BridgeBio Pharma in the 2nd quarter worth approximately $28,000. Finally, Allworth Financial LP acquired a new stake in BridgeBio Pharma during the second quarter valued at approximately $31,000. 99.85% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO Neil Kumar sold 10,000 shares of the firm's stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $69.08, for a total transaction of $690,800.00. Following the completion of the sale, the chief executive officer directly owned 495,686 shares in the company, valued at approximately $34,241,988.88. This trade represents a 1.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Maricel Apuli sold 2,000 shares of BridgeBio Pharma stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $80.06, for a total value of $160,120.00. Following the completion of the transaction, the chief accounting officer owned 127,401 shares in the company, valued at $10,199,724.06. The trade was a 1.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 56,980 shares of company stock valued at $4,578,119 over the last 90 days. 14.23% of the stock is currently owned by insiders.

Analyst Ratings Changes

BBIO has been the subject of a number of recent research reports. Citigroup lifted their price objective on BridgeBio Pharma from $82.00 to $93.00 and gave the stock a "neutral" rating in a research report on Thursday, July 16th. Cantor Fitzgerald restated an "overweight" rating on shares of BridgeBio Pharma in a report on Monday, October 5th. TD Cowen restated a "buy" rating on shares of BridgeBio Pharma in a report on Monday, October 5th. Piper Sandler raised their price target on shares of BridgeBio Pharma from $111.00 to $115.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 11th. Finally, Wells Fargo & Company lifted their price target on shares of BridgeBio Pharma from $98.00 to $102.00 and gave the stock an "overweight" rating in a report on Tuesday, August 11th. Twenty-one research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, BridgeBio Pharma currently has an average rating of "Moderate Buy" and a consensus price target of $105.42.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a biotechnology company focused on discovering, developing and commercializing medicines for genetically driven diseases. The company uses its drug discovery and development platform to advance therapies across areas including rare diseases, genetic disorders and precision oncology, with programs designed to address the underlying biological causes of disease.

BridgeBio operates through a collection of subsidiary companies and development programs. Its portfolio has included therapies for cardiovascular, endocrine, neurological and oncological conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.